Dr. San Miguel - Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma
Jesús San Miguel, MD Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain Member, IMF Board of Scientific Advisors
12.27.08
To view the video full screen, click on the small
button next to the volume control in the
lower right hand corner.
back
button next to the volume control in the
lower right hand corner.
print
related articles